We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
Read MoreHide Full Article
Moderna (MRNA - Free Report) announced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million.
The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on expanding and boosting its mRNA-manufacturing capabilities. It expects OriCiro's proprietary technologies to support its portfolio of mRNA-based therapeutics and vaccines.
OriCiro is focused on the development and commercialization of cell-free synthesis and amplification of plasmid DNA, which Moderna believes is a key component in mRNA manufacturing. OriCiro specializes in cell-free assembly and amplification technologies, offering an alternative to the conventional E. coli cloning process.
Shares of Moderna have declined 17.6% in the past one year compared with the industry’s 17.9% fall.
Image Source: Zacks Investment Research
Currently, Moderna generates all of its product revenues from the sale of its COVID-19 vaccines. The success achieved by the company in commercializing its COVID-19 vaccines has resulted in a significant boost to its cash resources. Moderna’s significant cash, cash equivalents, and marketable securities stood at approximately $17 billion at the end of September 2022.
As the effects of the pandemic have started to subside, Moderna has started to experience a declining trend in its COVID-19 vaccine sales. The trend is expected to continue in future quarters. As a result, the company has started to focus on its non-COVID pipeline and expand on that front.
Currently, Moderna has three late-stage candidates — mRNA-1647, mRNA-1345 and mRNA-1010 — in its pipeline, which are being developed as cytomegalovirus vaccine, respiratory syncytial virus vaccine and influenza vaccine, respectively. A successful development of any or all of these candidates and potential commercialization will help lower the company’s dependence on a single product for revenues.
Last month, Moderna, along with partner Merck (MRK - Free Report) , announced that the phase IIb KEYNOTE-942 study, evaluating their personalized cancer vaccine candidate mRNA-4157/V940, achieved its primary end-point of recurrence-free survival in melanoma patients.
Data from the above study showed that the combination of mRNA-4157 and Merck’s blockbuster cancer drug Keytruda exhibited a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 44% compared with Keytruda alone.
Based on this data, Moderna and Merck plan to discuss these results with regulatory authorities. Merck and Moderna also intend to start a phase III study in melanoma patients later this year.
In the past 60 days, estimates for Allogene’s 2022 loss per share have narrowed from $2.39 to $2.38. In the same period, the loss per share estimate for 2023 has narrowed from $2.84 to $2.82. Shares of Allogene have declined 57.8% in the past year.
Earnings of Allogene beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
In the past 60 days, estimates for AVEO Pharmaceuticals’ 2022 loss per share have narrowed from 76 cents to 68 cents. In the same period, earnings estimates for 2023 have risen from 46 cents per share to 52 cents. Shares of AVEO Pharmaceuticals have surged 233.5% in the past year.
Earnings of AVEO Pharmaceuticals beat estimates in three of the last four quarters, while missing the mark on one occasion, witnessing an earnings surprise of 19.87%, on average. In the last reported quarter, AVEO Pharmaceuticals’ earnings beat estimates by 43.75%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
Moderna (MRNA - Free Report) announced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million.
The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on expanding and boosting its mRNA-manufacturing capabilities. It expects OriCiro's proprietary technologies to support its portfolio of mRNA-based therapeutics and vaccines.
OriCiro is focused on the development and commercialization of cell-free synthesis and amplification of plasmid DNA, which Moderna believes is a key component in mRNA manufacturing. OriCiro specializes in cell-free assembly and amplification technologies, offering an alternative to the conventional E. coli cloning process.
Shares of Moderna have declined 17.6% in the past one year compared with the industry’s 17.9% fall.
Image Source: Zacks Investment Research
Currently, Moderna generates all of its product revenues from the sale of its COVID-19 vaccines. The success achieved by the company in commercializing its COVID-19 vaccines has resulted in a significant boost to its cash resources. Moderna’s significant cash, cash equivalents, and marketable securities stood at approximately $17 billion at the end of September 2022.
As the effects of the pandemic have started to subside, Moderna has started to experience a declining trend in its COVID-19 vaccine sales. The trend is expected to continue in future quarters. As a result, the company has started to focus on its non-COVID pipeline and expand on that front.
Currently, Moderna has three late-stage candidates — mRNA-1647, mRNA-1345 and mRNA-1010 — in its pipeline, which are being developed as cytomegalovirus vaccine, respiratory syncytial virus vaccine and influenza vaccine, respectively. A successful development of any or all of these candidates and potential commercialization will help lower the company’s dependence on a single product for revenues.
Last month, Moderna, along with partner Merck (MRK - Free Report) , announced that the phase IIb KEYNOTE-942 study, evaluating their personalized cancer vaccine candidate mRNA-4157/V940, achieved its primary end-point of recurrence-free survival in melanoma patients.
Data from the above study showed that the combination of mRNA-4157 and Merck’s blockbuster cancer drug Keytruda exhibited a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 44% compared with Keytruda alone.
Based on this data, Moderna and Merck plan to discuss these results with regulatory authorities. Merck and Moderna also intend to start a phase III study in melanoma patients later this year.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
Zacks Rank & Stocks to Consider
Moderna currently carries a Zacks Rank #3 (Hold). A couple of better-ranked companies in the overall healthcare sector are Allogene (ALLO - Free Report) and AVEO Pharmaceuticals , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Allogene’s 2022 loss per share have narrowed from $2.39 to $2.38. In the same period, the loss per share estimate for 2023 has narrowed from $2.84 to $2.82. Shares of Allogene have declined 57.8% in the past year.
Earnings of Allogene beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
In the past 60 days, estimates for AVEO Pharmaceuticals’ 2022 loss per share have narrowed from 76 cents to 68 cents. In the same period, earnings estimates for 2023 have risen from 46 cents per share to 52 cents. Shares of AVEO Pharmaceuticals have surged 233.5% in the past year.
Earnings of AVEO Pharmaceuticals beat estimates in three of the last four quarters, while missing the mark on one occasion, witnessing an earnings surprise of 19.87%, on average. In the last reported quarter, AVEO Pharmaceuticals’ earnings beat estimates by 43.75%.